港股異動 | 協鑫科技漲6% 年產400兆瓦單晶硅棒項目將進入批量生產
格隆匯2月1日丨協鑫科技(3800.HK)拉昇漲6%,現報2.29港元,暫成交5.6億港元,總市值620億港元。消息上,協鑫科技子公司中能硅業彩虹工程 CCZ(連續直拉單晶技術)設備及工藝開發項目首根超長單晶硅棒在本月出爐,棒體長5.1米,重量達600千克,較常規單晶棒延長42%,重量增加50%,產能提升25%。設備調試成功後,年產400兆瓦單晶硅棒項目進入批量生產。據瞭解,連續直拉法具有生產效率高、生產成本低,更適用N型硅片的特點。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.